BNTC, page-2

All time closing low today again on the ASX.

Hep B in vivo data expected in weeks (not months) is all that matters to me now.

Good results are obviously expected in which case the company's window is well and truly open. They already have the data but it is being packaged is my guess. They would not have switched their focus to Hep B without the data to support it is also my guess.

The stock is priced for failure.